On October 29, 2021 AbClon reported an additional material patent had been acquired (Press release, AbClon, OCT 29, 2021, View Source;wr_id=151 [SID1234638631]). This patent AC101 This is a follow-up patent in which stability enhancement technology was additionally applied to the patent.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AC101 Discovery used AbClone’s proprietary antibody discovery technology ‘NEST (Novel Epitope Screening Technology)’ The platform was utilized. This platform is a technology that newly discovers antibody binding sites on disease proteins, Antibody treatments developed through this process can exhibit different therapeutic effects depending on the epitope, so when a patent is acquired, it is different from other existing patented technologies targeting the same disease protein. It has the advantage of being relatively free.
This AC101’s follow-up patent has already been Separate from the existing AC101 patent registered in several countries, technology to improve stability has been applied, .Also, applications have been filed in the U.S. and Europe and examination is in progress. Japan, and Before China, registration was also completed in Korea, Australia
AC101is a disease protein HER2 (Human It is a monoclonal antibody treatment targeting Epidermal Growth Receptor 2). Herceptin, Perjeta, etc. HER2 Although it has been approved as a targeted antibody treatment, it is reported that treatments with strong anticancer effects are still rare in the treatment of stomach cancer.
AC101 was superior to Herceptin+Perjeta co-administration in animal models co-administered with Herceptin. It showed efficacy, this data shows that AbClone Shanghai Henrius Biotech(hereinafter referred to as Henrius)at AC101 was an opportunity to transfer technology.
Henlius targeted stomach cancer last 9month. AC101 (Henrius codename: HLX22) and Herceptin biopsy miller In the combination clinical trial2, administration to the first patient began. Through advanced clinical trial1phase 2Dosage(25mg/kg) It has been decided, to be clinically targeted as the first standard treatment for gastric cancer patients. 2award is in progress. According to these results, AppClone’s follow-up milestones and royalties will be determined. Additional profits are also expected.
Company officials said "AC101 with improved stability Stronger intellectual property rights were secured through additional patent registration" "In the future, through the commercialization of AC101, our company will also be available in the global market. NEST expects that its platform technology will be recognized" revealed.